title: Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study.
abstract: BACKGROUND
  This study aimed to compare glucose variability in patients given the α-glucosidase inhibitors miglitol and acarbose using continuous glucose monitoring (CGM).
  
  
  METHODS
  Ten type 2 diabetes patients were hospitalized for 4 days, and their glucose levels were measured using CGM. Patients were given miglitol (50 mg) or acarbose (100 mg) before each meal on Day 2, and vice versa on Day 3, in a randomized crossover design. The patients had three identical test meals on Days 2 and 3. The CGM data were used to compare each parameter for glycemic variability after each of the three meals.
  
  
  RESULTS
  No significant differences were observed between miglitol treatment or acarbose treatment in regard to the range of increase in glucose levels from baseline to peak, time to peak postprandial glucose levels from the preprandial period, and area under the curve for glycemic variability from the preprandial period to 3 h after each meal. However, the range of increase in glucose levels at 30 min (0.4 vs. 30.7 mg/dL, P < 0.0001) and 60 min (32.8 vs. 67.5 mg/dL, P <0.0001) after lunch and 30, 60, and 90 min after dinner (3.3 vs. 22.2 mg/dL, P = 0.0249; 36.6 vs. 67.5 mg/dL, P < 0.0001; and 60.5 vs. 81.6 mg/dL, P = 0.0073, respectively) was significantly smaller in miglitol treatment compared with acarbose treatment.
  
  
  CONCLUSIONS
  In a pilot study with a crossover design in 10 type 2 diabetes patients, it was shown that although there was no significant difference in glucose variability with miglitol or acarbose after a fat-rich diet, glucose increases was significantly reduced with miglitol after a meal comprising typical Japanese diet 60-90 min postprandially.
authors.affiliation: Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan. dtsujino@gmail.com
authors.forename: Daisuke
authors.initials: D
authors.lastname: Tsujino
authors.forename: Rimei
authors.initials: R
authors.lastname: Nishimura
authors.forename: Kentaro
authors.initials: K
authors.lastname: Taki
authors.forename: Aya
authors.initials: A
authors.lastname: Morimoto
authors.forename: Naoko
authors.initials: N
authors.lastname: Tajima
authors.forename: Kazunori
authors.initials: K
authors.lastname: Utsunomiya
mesh_terms: D017485:1-Deoxynojirimycin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D020909:Acarbose / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D019540:Area Under Curve; D001786:Blood Glucose / Q000378:metabolism*; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy* / Q000201:enzymology; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D005260:Female; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000201:enzymology / Q000517:prevention & control*; D007564:Japan; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D055815:Young Adult; D000520:alpha-Glucosidases / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; C045621:miglitol; D017485:1-Deoxynojirimycin; D000520:alpha-Glucosidases; D020909:Acarbose